Corporate News
Change of preliminary results date
31 August 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition products, announces that the publication of the preliminary results for the year ended 31 March 2022 will be further delayed as the Company and its auditors require additional time to finalise the accounting treatment and disclosures relating to the recent sale of the CD4 business and for the Company’s auditors to complete their transactional testing. This work is now expected to be completed in mid-September.
The delay to publication now means that the AGM planned for 5 October 2022 will no longer take place and a revised date will be communicated shortly.
Contacts:
| Omega Diagnostics Group PLC | www.omegadx.com |
| Jag Grewal Chief Executive Officer | via Walbrook PR |
| Chris Lea, Chief Financial Officer | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | |
| Alice Lane/ Harriet Ward (ECM) | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Applegarth | Mob: 07584 391 303 |
| Sam Allen | Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and is now focused on the health and nutrition sector.
